Autolus Therapeutics plc Operating Cash Flow
Autolus Therapeutics plc (AUTL) reported Operating Cash Flow of -$90.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Autolus Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$25.07M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$65.32M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$67.32M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$67.90M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for fiscal 2025 was -$283.57M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for fiscal 2024 was -$206.27M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for fiscal 2023 was -$145.59M.
- Autolus Therapeutics plc net cash provided by (used in) operating activities for fiscal 2022 was -$112.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$25.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$90.39M 10-Q · filed 2026-08-11 | -$157.71M derived: sum of 3 quarters · filed 2026-08-11 | -$225.61M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$65.32M 10-Q · filed 2026-05-14 | -$132.64M derived: sum of 2 quarters · filed 2026-05-14 | -$200.54M derived: sum of 3 quarters · filed 2026-05-14 | -$273.32M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$67.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$135.22M derived: sum of 2 quarters · filed 2026-03-27 | -$208.00M derived: sum of 3 quarters · filed 2026-08-11 | -$283.57M 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$67.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$140.68M derived: sum of 2 quarters · filed 2026-08-11 | -$216.25M 10-Q · filed 2025-11-12 | -$254.18M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$72.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$148.35M 10-Q · filed 2026-08-11 | -$186.28M derived: sum of 3 quarters · filed 2026-08-11 | -$263.02M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$75.56M 10-Q · filed 2026-05-14 | -$113.50M derived: sum of 2 quarters · filed 2026-05-14 | -$190.24M derived: sum of 3 quarters · filed 2026-05-14 | -$241.32M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$37.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$114.67M derived: sum of 2 quarters · filed 2026-03-27 | -$165.76M derived: sum of 3 quarters · filed 2026-03-27 | -$206.27M 10-K · filed 2026-03-27 | |
| 2024-09-30 | -$76.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$127.82M derived: sum of 2 quarters · filed 2025-11-12 | -$168.34M 10-Q · filed 2025-11-12 | -$193.17M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$51.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$91.60M 10-Q · filed 2025-08-12 | -$116.43M derived: sum of 3 quarters · filed 2025-08-12 | -$156.62M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$40.51M 10-Q · filed 2025-05-08 | -$65.35M derived: sum of 2 quarters · filed 2025-05-08 | -$105.53M derived: sum of 3 quarters · filed 2025-05-08 | -$143.68M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$24.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$65.02M derived: sum of 2 quarters · filed 2025-03-20 | -$103.17M derived: sum of 3 quarters · filed 2025-03-20 | -$145.59M 10-K · filed 2025-03-20 | |
| 2023-09-30 | -$40.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$78.33M derived: sum of 2 quarters · filed 2024-11-12 | -$120.75M 10-Q · filed 2024-11-12 | -$135.32M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$38.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$80.57M 10-Q · filed 2024-08-08 | -$95.13M derived: sum of 3 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$42.42M 10-Q · filed 2024-05-17 | -$56.98M derived: sum of 2 quarters · filed 2024-05-17 | |||
| 2022-12-31 | -$14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$112.31M 10-K · filed 2024-03-21 | |||
| 2022-09-30 | -$97.74M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | -$117.86M 10-K · filed 2024-03-21 | ||||
| 2021-03-31 | -$37.34M 6-K · filed 2021-05-06 | -$65.07M derived: sum of 2 quarters · filed 2023-03-07 | -$104.14M derived: sum of 3 quarters · filed 2023-03-07 | -$131.07M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2020-12-31 | -$27.73M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | -$66.79M derived: sum of 2 quarters · filed 2023-03-07 | -$93.72M derived: sum of 3 quarters · filed 2023-03-07 | -$117.76M 20-F · filed 2023-03-07 | |
| 2020-09-30 | -$39.06M derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | -$66.00M derived: sum of 2 quarters · filed 2020-11-05 | -$90.03M 6-K · filed 2020-11-05 | -$123.30M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | -$26.93M derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | -$50.97M 6-K · filed 2020-08-06 | -$84.23M derived: sum of 3 quarters · filed 2022-03-10 | -$108.72M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | -$24.03M 6-K · filed 2021-05-06 | -$57.30M derived: sum of 2 quarters · filed 2022-03-10 | -$81.79M derived: sum of 3 quarters · filed 2022-03-10 | -$99.00M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | -$33.27M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | -$57.75M derived: sum of 2 quarters · filed 2022-03-10 | -$74.97M derived: sum of 3 quarters · filed 2022-03-10 | -$101.48M 20-F · filed 2022-03-10 | |
| 2019-09-30 | -$24.49M derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | -$41.70M derived: sum of 2 quarters · filed 2020-11-05 | -$68.22M 6-K · filed 2020-11-05 | -$88.00M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | -$17.21M derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | -$43.73M 6-K · filed 2020-08-06 | -$63.52M derived: sum of 3 quarters · filed 2021-03-04 | -$80.68M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | -$26.52M 6-K · filed 2020-05-07 | -$46.30M derived: sum of 2 quarters · filed 2021-03-04 | -$63.47M derived: sum of 3 quarters · filed 2021-03-04 | ||
| 2018-12-31 | -$19.79M 20-F · filed 2021-03-04 | -$36.95M derived: sum of 2 quarters · filed 2021-03-04 | |||
| 2018-09-30 | -$17.16M derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | -$31.54M 20-F · filed 2021-03-04 | -$22.74M 6-K · filed 2019-11-07 | -$31.54M 20-F · filed 2020-03-03 | |
| 2018-06-30 | -$14.37M 6-K · filed 2019-08-08 | ||||
| 2017-12-31 | -$8.80M 20-F · filed 2019-02-25 | ||||
| 2017-09-30 | -$16.36M 20-F · filed 2020-03-03 | ||||
| 2016-09-30 | -$9.85M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |